Abundant CAD-related genes detected by GWAS may be druggable, as evidenced by the fact that many candidate responsible genes at CAD loci are medical drug targets, including 3-hydroxy-3- methylglutaryl-coenzyme A reductase (HMGCR) (statins), APOB (Mipomersen), and PCSK9 (respective antibodies or inhibitors), as well as gene targets currently undergoing pre-clinical evaluations [30,31]. This evidence concerns the gene HMGCR and coronary artery disorder.